| Symbol | ACRV |
|---|---|
| Name | ACRIVON THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 480 ARSENAL WAY,SUITE 100, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | 6172078979.0 |
| Fax | — |
| — | |
| Website | https://www.acrivon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001781174 |
| Description | Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The companys Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Additional info from NASDAQ: |
Levin Michaela 🟢 acquired 160.0K shares (1 derivative) of Acrivon Therapeutics, Inc. (ACRV) at $2.09 Transaction Date: Aug 31, 2026 | Filing ID: 004065
Read moreNew Form 3 - Acrivon Therapeutics, Inc. <b>Filed:</b> 2026-09-02 <b>AccNo:</b> 0000905148-26-004064 <b>Size:</b> 14 KB
Read moreAcrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Read moreAcrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Read moreBlume-Jensen Peter 🔴 sold 14.0K shares of Acrivon Therapeutics, Inc. (ACRV) at $2.21 Transaction Date: Aug 25, 2026 | Filing ID: 003968
Read more📋 Peter Blume-Jensen (Officer) plans to sell 14K shares of Acrivon Therapeutics, Inc. (at $2.18 each, total $31K) Filed: Aug 25, 2026 | ID: 003924
Read morePeterson Katharine 🔴 sold 101 shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 Transaction Date: Aug 18, 2026 | Filing ID: 003840
Read moreMiller Mary 🔴 sold 185 shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 Transaction Date: Aug 18, 2026 | Filing ID: 003839
Read moreGamelin Erick 🔴 sold 400 shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 Transaction Date: Aug 18, 2026 | Filing ID: 003838
Read moreDevroe Eric 🔴 sold 604 shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 Transaction Date: Aug 18, 2026 | Filing ID: 003837
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06667141 | Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase1 | Specific Advanced Solid Tumors | Recruiting | 2024-10-08 | 2026-12-12 | ClinicalTrials.gov |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Phase2 | Head and Neck Squamous Cell Carcinoma | Recruiting | 2024-09-25 | 2028-08-23 | ClinicalTrials.gov |
| NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase2 | Endometrial Adenocarcinoma | Recruiting | 2022-08-29 | 2027-11-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06597565 |
| Gemcitabine | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06597565 |
| OncoSignature | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| Gemcitabine | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-368 | Other | Phase PHASE2 | Endometrial Adenocarcinoma | RECRUITING | NCT05548296 |
| ACR-2316 | Other | Phase PHASE1 | Specific Advanced Solid Tumors | RECRUITING | NCT06667141 |